ArticlePloS one2012
CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Tissue-specific cancer stem/progenitor cells: Therapeutic implications.World journal of stem cells · 2023Review
- Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer.Oncology letters · 2022Article
- Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling.Medical oncology (Northwood, London, England) · 2021Article
- Vitamin D sufficiency enhances differentiation of patient-derived prostate epithelial organoids.iScience · 2021Article
- Stromal-AR influences the growth of epithelial cells in the development of benign prostate hyperplasia.Molecular and cellular biochemistry · 2020Article
- Peptide-Targeted Polyplexes for Aerosol-Mediated Gene Delivery to CD49f-Overexpressing Tumor Lesions in Lung.Molecular therapy. Nucleic acids · 2019Article
- Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.Medicines (Basel, Switzerland) · 2019Review
- Cancer stem cell impact on clinical oncology.World journal of stem cells · 2018Review
- Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models.Cold Spring Harbor perspectives in medicine · 2018Review
- Sphere-Formation Assay: Three-DimensionalFrontiers in oncology · 2018Article
- Cell surface Thomsen-Friedenreich proteome profiling of metastatic prostate cancer cells reveals potential link with cancer stem cell-like phenotype.Oncotarget · 2017Article
- Article
- Angiogenic potency evaluation of cell therapy candidates by a novel application of the in vitro aortic ring assay.Stem cell research & therapy · 2017Article
- The Role of Integrin α6 (CD49f) in Stem Cells: More than a Conserved Biomarker.Stem cells and development · 2017Review
- Cancer stem cells (CSCs), cervical CSCs and targeted therapies.Oncotarget · 2017Review
- Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate Cancer.Stem cells translational medicine · 2017Article
- Overexpression of Thy1 and ITGA6 is associated with invasion, metastasis and poor prognosis in human gallbladder carcinoma.Oncology letters · 2016Article
- Preservation of KIT genotype in a novel pair of patient-derived orthotopic xenograft mouse models of metastatic pediatric CNS germinoma.Journal of neuro-oncology · 2016Article
- ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.Molecular cancer · 2016Article
- Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate.American journal of physiology. Renal physiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Stem cells may play a role in the development and maintenance of proliferative diseases of the prostate such as prostate cancer and benign prostatic hyperplasia. Cell membrane protein markers, CD49f, CD133 and CD44, have been shown to identify putative prostate stem cells, but a lack of consensus exists with regards to the most efficient marker(s) for stem-like cell identification. This study aimed to determine whether previously reported markers had equal capacity to select monolayer and spheroid colony-forming cells (CFCs), which were used as surrogate readouts of stem-like cells, and to characterize the expression of CD49f, CD44 and CD133 by flow cytometry and immunohistochemistry.In benign prostate cells, CD49f+, CD44+, and CD133+ cells represented 5.6±3.1%, 28.2±4.1% and 0.10±0.06% of total cells. Both monolayer- and spheroid-CFCs existed at a frequency of approximately 0.5% of total cells. CD49f+, CD44+, and CD133+ subpopulations differed significantly in their ability to select benign CFCs. The highest recovery of CFCs was achieved by CD49f+ selection (98%), whereas CD44+ or CD133+ selection led to poor CFC-recovery (17% and 3%, respectively). For the first time, we show highly efficient recovery of CFCs from advanced prostate cancer by CD49f+, but not by CD44+ or CD133+ selection. Furthermore, CD133 expression (AC133 clone) could not be detected in benign prostate cells by either immunohistochemistry or flow cytometry. We conclude that CD49f, but not previously described stem cell markers CD133 and CD44, to be optimal for selection of monolayer- and spheroid-CFCs in the benign and malignant prostate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.